ResearcherUniversity of MichiganActive in the last 2 years
David M. Karnak
Matched on ORCID iD 0009-0007-8861-9041; OpenAlex author ID A5063618332. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 24
2012: 1 paper · 2013: 2 papers · 2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper
Papers 6
- Olaparib and Radiotherapy Induce Type I Interferon- and CD8+ T Cell-Dependent Sensitization to Immunotherapy in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-24-0210↗
- DNA-PK Inhibition and Radiation Promote Antitumoral Immunity through RNA Polymerase III in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-21-0725↗
- Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-14-1038↗
- Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776. Co-author DOI 10.1158/1078-0432.ccr-12-3748↗
- HAb18G/CD147 promotes pSTAT3-mediated pancreatic cancer development via CD44s. Co-author DOI 10.1158/1078-0432.ccr-13-0621↗
- Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer. Co-author DOI 10.1158/1535-7163.mct-12-0098↗
Closest collaborators
The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Theodore Steven Lawrence · 6 shared papers, 2012–2025 · strength 0.44
- Paper Olaparib and Radiotherapy Induce Type I Interferon- and CD8+ T Cell-Dependent Sensitization to Immunotherapy in Pancrea… DOI 10.1158/1535-7163.mct-24-0210↗
- Paper DNA-PK Inhibition and Radiation Promote Antitumoral Immunity through RNA Polymerase III in Pancreatic Cancer. DOI 10.1158/1541-7786.mcr-21-0725↗
- Paper Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer. DOI 10.1158/1078-0432.ccr-14-1038↗
- Leslie A. Parsels · 4 shared papers, 2013–2025 · strength 0.39
- Paper Olaparib and Radiotherapy Induce Type I Interferon- and CD8+ T Cell-Dependent Sensitization to Immunotherapy in Pancrea… DOI 10.1158/1535-7163.mct-24-0210↗
- Paper DNA-PK Inhibition and Radiation Promote Antitumoral Immunity through RNA Polymerase III in Pancreatic Cancer. DOI 10.1158/1541-7786.mcr-21-0725↗
- Paper Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer. DOI 10.1158/1078-0432.ccr-14-1038↗
- Meredith Ann Morgan · 4 shared papers, 2013–2025 · strength 0.39
- Paper Olaparib and Radiotherapy Induce Type I Interferon- and CD8+ T Cell-Dependent Sensitization to Immunotherapy in Pancrea… DOI 10.1158/1535-7163.mct-24-0210↗
- Paper DNA-PK Inhibition and Radiation Promote Antitumoral Immunity through RNA Polymerase III in Pancreatic Cancer. DOI 10.1158/1541-7786.mcr-21-0725↗
- Paper Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer. DOI 10.1158/1078-0432.ccr-14-1038↗
- Qiang Zhang · 2 shared papers, 2022–2025 · strength 0.32
- Paper Olaparib and Radiotherapy Induce Type I Interferon- and CD8+ T Cell-Dependent Sensitization to Immunotherapy in Pancrea… DOI 10.1158/1535-7163.mct-24-0210↗
- Paper DNA-PK Inhibition and Radiation Promote Antitumoral Immunity through RNA Polymerase III in Pancreatic Cancer. DOI 10.1158/1541-7786.mcr-21-0725↗
- Alnawaz Rehemtulla · 2 shared papers, 2012–2025 · strength 0.21
- Paper Olaparib and Radiotherapy Induce Type I Interferon- and CD8+ T Cell-Dependent Sensitization to Immunotherapy in Pancrea… DOI 10.1158/1535-7163.mct-24-0210↗
- Paper Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer. DOI 10.1158/1535-7163.mct-12-0098↗
- Eileen S. Carpenter · 1 shared paper, 2025 · strength 0.18
- Victoria M. Valvo · 1 shared paper, 2025 · strength 0.18
- Vaibhav Sahai · 1 shared paper, 2025 · strength 0.18
- Matthew T. McMillan · 1 shared paper, 2022 · strength 0.13
- Timothy L. Frankel · 1 shared paper, 2022 · strength 0.13
- Weiwei Wang · 1 shared paper, 2022 · strength 0.13
- Jonathan Maybaum · 2 shared papers, 2013–2014 · strength 0.07
- Carl G. Engelke · 2 shared papers, 2013–2014 · strength 0.07
- Dongping Wei · 2 shared papers, 2013–2014 · strength 0.07
- Zhi‐Nan Chen · 1 shared paper, 2013 · strength 0.03
- Liang Xu · 1 shared paper, 2013 · strength 0.03
- Ling Li · 1 shared paper, 2013 · strength 0.03
- Jiayuh Lin · 1 shared paper, 2013 · strength 0.03
- Xiaoqing Wu · 1 shared paper, 2013 · strength 0.03
- Qiang Zhang · 1 shared paper, 2013 · strength 0.03
- Diane M. Simeone · 1 shared paper, 2013 · strength 0.03
- Brian Dale Ross · 1 shared paper, 2012 · strength 0.03
- Judith S. Sebolt · 1 shared paper, 2012 · strength 0.03
- Terence Marques Williams · 1 shared paper, 2012 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.